Proteon Adds $15M; Getting Closer to Novartis Option
By Jennifer Boggs
Monday, August 15, 2011
About four months after kicking off a Phase II study of lead product PRT-201 , which, if positive, could entice a buyout bid from Novartis AG under a 2009 option deal, Proteon Therapeutics Inc. is padding its coffers with a $15.2 million financing.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.